The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma.
about
pRb inactivation in mammary cells reveals common mechanisms for tumor initiation and progression in divergent epitheliaKnockout and transgenic mice of Trp53: what have we learned about p53 in breast cancer?How changes in extracellular matrix mechanics and gene expression variability might combine to drive cancer progressionEffects of enriched environment on COX-2, leptin and eicosanoids in a mouse model of breast cancerSTX140, but not paclitaxel, inhibits mammary tumour initiation and progression in C3(1)/SV40 T/t-antigen transgenic miceThe epigenetic modifier JMJD6 is amplified in mammary tumors and cooperates with c-Myc to enhance cellular transformation, tumor progression, and metastasisSuccessful chemoimmunotherapy against hepatocellular cancer in a novel murine model.Exercise training in transgenic mice is associated with attenuation of early breast cancer growth in a dose-dependent mannerA transgenic mouse model of metastatic carcinoma involving transdifferentiation of a gastric epithelial lineage progenitor to a neuroendocrine phenotypeTranscriptomic signature of bexarotene (rexinoid LGD1069) on mammary gland from three transgenic mouse mammary cancer models.Maternal consumption of canola oil suppressed mammary gland tumorigenesis in C3(1) TAg mice offspring.Identification of a stable molecular signature in mammary tumor endothelial cells that persists in vitro.Uncoupling genotoxic stress responses from circadian control increases susceptibility to mammary carcinogenesis.Aberrant Proliferation of Differentiating Alveolar Cells Induces Hyperplasia in Resting Mammary Glands of SV40-TAg Transgenic MiceSocial isolation reduces mammary development, tumor incidence, and expression of epigenetic regulators in wild-type and p53-heterozygotic mice.Weight Loss Reversed Obesity-Induced HGF/c-Met Pathway and Basal-Like Breast Cancer ProgressionMullerian inhibiting substance suppresses tumor growth in the C3(1)T antigen transgenic mouse mammary carcinoma modelA single vector containing modified cre recombinase and LOX recombination sequences for inducible tissue-specific amplification of gene expression.Somatic expression of PyMT or activated ErbB2 induces estrogen-independent mammary tumorigenesis.Genetically engineered rodent models of mammary gland carcinogenesis: an overview.T(2)∗ relaxation times of intraductal murine mammary cancer, invasive mammary cancer, and normal mammary gland.Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases.Bioactive dietary supplements reactivate ER expression in ER-negative breast cancer cells by active chromatin modificationsSilencing HoxA1 by intraductal injection of siRNA lipidoid nanoparticles prevents mammary tumor progression in mice.Obesity-mediated regulation of HGF/c-Met is associated with reduced basal-like breast cancer latency in parous mice.Transforming functions of Simian Virus 40.Mouse models of breast cancer metastasis.In vivo MRI of early stage mammary cancers and the normal mouse mammary glandDetection of in situ mammary cancer in a transgenic mouse model: in vitro and in vivo MRI studies demonstrate histopathologic correlation.Dietary walnut suppressed mammary gland tumorigenesis in the C(3)1 TAg mouseT antigens of simian virus 40: molecular chaperones for viral replication and tumorigenesisHigh resolution 3D MRI of mouse mammary glands with intra-ductal injection of contrast media.Molecular markers and therapeutic targets in ductal carcinoma in situ.Mammary cancer initiation and progression studied with magnetic resonance imaging.Pathologic progression of mammary carcinomas in a C3(1)/SV40 T/t-antigen transgenic rat model of human triple-negative and Her2-positive breast cancer.Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer.A novel prodrug of epigallocatechin-3-gallate: differential epigenetic hTERT repression in human breast cancer cells.Prolactin induces ERalpha-positive and ERalpha-negative mammary cancer in transgenic miceGenetically engineered mice as experimental tools to dissect the critical events in breast cancerThe serine protease inhibitor elafin maintains normal growth control by opposing the mitogenic effects of neutrophil elastase.
P2860
Q21090243-0D960A8E-8212-43AD-B18E-433CA30C7D70Q24802378-646E62AF-CB88-4D6E-998F-F50F54A9BADFQ27304881-D4D48998-368F-4C4F-80B6-E8FBE918EA98Q27330395-84F855AA-C0BA-4BB0-B656-FF44ED4A1E9EQ28536340-CEFA4F57-561B-411C-B618-12BF6571E3BDQ29544441-F46E44C0-3DBA-4CE6-8793-E0E3EE0F9AEDQ30276134-823DDD68-4922-41CF-A8E2-406F63CB9713Q31145811-3DAAF7EE-232C-4395-A56E-030A577134CAQ33201186-4AB79669-769D-417D-86BD-74012B62DFE4Q33368864-7E86741B-3963-428E-A002-EA6E8DBB61EEQ33537464-3AC5D30A-73BC-442F-9917-F40F34DD0D9BQ33645711-CD7206E4-BF80-4607-B849-7175670A0F28Q33779238-18E13A93-3CBE-4775-B01F-5496968435C1Q33809166-6250A69A-62A0-4CA5-A07A-5AD87B53006DQ33833579-ECF2F61A-3A62-46BF-BAC1-1958C9D80903Q33859809-BA91963B-005F-414F-AADD-FE1C15A86D2EQ33927553-ADF3FFE8-D4CF-4D27-A25B-A0DF31C65D50Q33939630-24619D60-87A8-415D-9F6F-C11BBEDF28D5Q34105355-05207C91-00D1-44DF-8D53-39690A67B1B2Q34160186-9EC3DEDC-A136-4EF3-B332-EC1AAFEF84BAQ34180249-553EAE93-3B23-4D14-A08C-650A98B1BFF9Q34272277-A7F65B07-C79F-4B34-830C-F09A3A0EEB76Q34291226-800DB53C-60DE-44B9-8838-8D85C2989151Q34395225-B53B7863-8150-4388-A673-DF1F664BE0ACQ34420979-4CFBCE2C-9284-4485-B82D-FCDF9CCB4684Q34468794-562E85E6-8D31-430C-9C62-F1CE22D2CD59Q34553964-5BDC1599-D076-48A2-8C8A-FFB2F9384626Q34610711-B3008C50-B7E2-4242-B0D1-3B0A1673C488Q34610869-EF9EB249-0C8F-491F-86EC-4D2DFD0C575BQ34631090-D8AB2153-FB55-40A4-9204-8D41E1AAD737Q34662543-4ABCCF8B-80ED-41D0-B199-04A9A07B73FEQ34714102-6907B23F-C0E4-4A2F-8BBC-2BB66928A593Q34872645-C3B38F3F-2CBD-4B3A-AA6A-61CA507151BEQ35000718-3A62613E-584F-4AD8-90DE-1EEFB3211CBAQ35010102-576DD2C6-7ABE-4607-9D1F-28DC931E2026Q35029548-C1B77A58-0B52-4378-865E-06AF1160E0DCQ35082328-27A4253B-91C7-4F3D-84BE-0253A668367AQ35121912-78BCA990-2D54-482B-8125-61AD9EFC50B8Q35146602-57B4F832-254F-44EF-AB46-0182DC34953EQ35185357-BE10F2A6-E7BD-4BCD-BD4D-62FDD25BB0AB
P2860
The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma.
description
2000 nî lūn-bûn
@nan
2000 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
The C3(1)/SV40 T-antigen trans ...... tage progression to carcinoma.
@ast
The C3(1)/SV40 T-antigen trans ...... tage progression to carcinoma.
@en
type
label
The C3(1)/SV40 T-antigen trans ...... tage progression to carcinoma.
@ast
The C3(1)/SV40 T-antigen trans ...... tage progression to carcinoma.
@en
prefLabel
The C3(1)/SV40 T-antigen trans ...... tage progression to carcinoma.
@ast
The C3(1)/SV40 T-antigen trans ...... tage progression to carcinoma.
@en
P2093
P356
P1433
P1476
The C3(1)/SV40 T-antigen trans ...... tage progression to carcinoma.
@en
P2093
Couldrey C
Kaczmarczyk S
Shibata MA
P2888
P304
P356
10.1038/SJ.ONC.1203280
P407
P577
2000-02-01T00:00:00Z
P5875
P6179
1005683287